The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World

Ravi Jhaveri*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther.

Original languageEnglish (US)
Pages (from-to)702-710
Number of pages9
JournalClinical Therapeutics
Volume43
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • COVID
  • SARS-CoV-2
  • baculovirus
  • recombinant adenovirus
  • vaccines

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World'. Together they form a unique fingerprint.

Cite this